Taiko Pharmaceutical Co.,Ltd.

4574

JP3442200006

Pharmaceuticals

Delayed Japan Exchange Other stock markets 09:55:36 2024-04-24 pm EDT			5-day change	1st Jan Change
339 ^JPY	-2.02%		-2.59%	+11.88%

Feb. 09	Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2024	CI
2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI

Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year ending December 31, 2022

August 12, 2022 at 02:30 am EDT

Taiko Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales to be JPY 6,000 million, operating loss to be JPY 2,800 million, net loss to be JPY 3,300 million and Basic loss per share to be JPY 75.67.

Latest news about Taiko Pharmaceutical Co.,Ltd.

Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2024	Feb. 09	CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	Dec. 22	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2023	Nov. 10	CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	23-09-23	CI
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical	23-08-15	MT
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2023	23-08-10	CI
Cuorips Inc. has completed an IPO in the amount of Â¥3.432 billion.	23-06-27	CI
Taiko Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical	23-04-25	MT
Taiko Pharmaceutical to Pay 607 Million Yen Penalty; Shares Down 3%	23-04-12	MT
Easing Wholesale Inflation Strengthens Japanese Shares; Orix, Partners Near Government Approval for Japan's First Casino Resort	23-04-12	MT
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2023	23-02-10	CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	22-11-11	CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year ending December 31, 2022	22-08-12	CI
Taiko Pharmaceutical Co.,Ltd. Omits to Pay Year-End Dividend for the Year Ended December 31, 2021	22-02-18	CI
Taiko Pharmaceutical Co.,Ltd. acquired Torishi S.A. de C.V.	21-12-12	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-11-09	CI
Certain Common Stock of Almado, Inc. are subject to a Lock-Up Agreement Ending on 21-SEP-2021.	21-09-20	CI
Taiko Pharmaceutical Co.,Ltd. Announces Earnings Results for the Second Quarter of 2021	21-08-06	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-08-06	CI
Almado, Inc. has completed an IPO in the amount of ¥4.664 billion.	21-06-24	CI
Almado, Inc. has filed an IPO.	21-05-21	CI
Taiko Pharmaceutical Co.,Ltd. Announces Earnings Results for the First Quarter of 2021	21-05-07	CI
Taiko Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Second Quarter and Year End of 2021	21-05-07	CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Quarter End December 2021	21-05-07	CI

Chart Taiko Pharmaceutical Co.,Ltd.

Duration

Period

More charts

Company Profile

TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
TAIKO PHARMACEUTICAL CO.,LTD.	+11.88%	107M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.97%	42.77B
OTSUKA HOLDINGS CO., LTD.	+19.38%	22.23B
SANDOZ GROUP AG	+13.12%	14.44B
CIPLA LIMITED	+12.19%	13.05B
ZYDUS LIFESCIENCES LIMITED	+35.45%	11.59B
ONO PHARMACEUTICAL CO., LTD.	-8.98%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	4.97B

Generic Pharmaceuticals